Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... of the "ADME-Toxicology Testing - Global Strategic Business ... report analyzes the worldwide markets for ADME-Toxicology Testing in ... & In-Vitro), and ADME Testing. The report ... Canada , Japan , ...
(Date:4/17/2015)... N.J. and DETROIT , April ... five children live in poverty, the infant mortality rate is ... at 15 per 1,000 live births. Nearly 6 of 10 ... not receive adequate prenatal care.  These are sobering statistics that ... serving the people of Metro Detroit, is poised to change ...
(Date:4/17/2015)... April 17, 2015  Over the next five years, the ... grow, with ArcView predicting that 14 more states will legalize ... The U.S. market for legal cannabis grew 74 percent in ... Analysts project the market could grow more than fourfold to ... soften their stance on marijuana. Cannabiz Mobile Inc. ...
Breaking Medicine Technology:ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... China, Oct. 11 Merial, the Animal Health ... SNY ), announced today that Merial Animal Health Co. (China) ... plant located in the Nanchang Hi-tech Development Zone, China. ... and the Group,s first production facility in China has been ...
... , EMERYVILLE, Calif., Oct. 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ... teleconference with management to provide a general business update on ... a.m. Pacific Time). , Interested parties may access a ... http://www.onyx-pharm.com/view.cfm/32/Event-Calendar , or by dialing 847-413-3362 ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3
(Date:4/17/2015)... April 17, 2015 Alcohol and Violence ... (NCADD) notes that drinking and driving has been the ... the same time, the link between alcohol and crime ... abuse and violence and sexual assault, and their relationship ... the NCADD, 5.3 million adults in America were drinking ...
(Date:4/17/2015)... From the day Dr. Todd Phillips founded The ... has empowered young people to create meaningful change in their ... water and the Gospel to all of Liberia by 2020 ... and 27, students, faculty and staff raised $21,000 through the ... and the Good News of Jesus. , During the ...
(Date:4/17/2015)... Representatives Jim Himes (D-CT) and Ed ... HR 1849 in congress on April 16, 2015 in ... patients with the genetic disease. , The bill, ... the first to create a federally led and financed ... hemorrhagic telangiectasia. This would effectively prevent premature death and ...
(Date:4/17/2015)... At the end of February 2015, Choices Recovery ... the Oscars” in the Stardust Penthouse on the rooftop ... Los Angeles skyline. These events honoring the 2015 Oscar ... producer of sustainable product placement in TV and film. ... of eco-friendly and socially conscious products and services, the ...
(Date:4/17/2015)... Baptist Health and The University of Texas ... designed to transform oncology care in northeast Florida and ... create a joint cancer program to enhance patient access ... MD Anderson Cancer Center is anticipated to open in ... highly coordinated, multidisciplinary cancer care for adults in the ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... with first product sales since 2005, SEATTLE, May ... reported financial results for the quarter ended,March 31, 2008. ... $20,000 for the first quarter of 2007. Gross product ... first quarter of 2008., Total operating expenses increased ...
... Holdings, Inc. ("Holdings",or the "Company"), the parent company ... nation,s largest cancer services companies, reported revenue of,$810.6 ... cash flow of,$50.9 million for the quarter ended ... include those of US Oncology, its wholly-owned,subsidiary, through ...
... CorVel Corporation,(Nasdaq: CRVL ) announced today that Gordon ... Bank of America 2008 Health Care Services,Conference on Tuesday, ... be,held at the Four Seasons Hotel in Las Vegas, ... through a webcast on,CorVel,s website, http://www.corvel.com . To ...
... result of San Diego State,University,s interim suspension ... supports the decisions of our,member fraternities to ... parties accountable for their actions. The NIC, ... with our member organizations and San,Diego State ...
... Inter-Con Security Officers Report They Don,t Have Healthcare, ... OAKLAND, Calif., May 7 In the ... increasing,number of security officers report they either don,t ... their families., Kaiser contractor Inter-Con Security is ...
... ALEXANDRIA, Va., May 7 The American Physical,Therapy ... coalition of,health and consumer groups to advocate for ... Safety of Seniors Act., In remarks during ... and National Falls Free Coalition representative Bonita,Lynn Beattie, ...
Cached Medicine News:Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 2Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 3Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 4Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 5Health News:Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results 6Health News:US Oncology Reports First Quarter 2008 Results 2Health News:US Oncology Reports First Quarter 2008 Results 3Health News:US Oncology Reports First Quarter 2008 Results 4Health News:US Oncology Reports First Quarter 2008 Results 5Health News:US Oncology Reports First Quarter 2008 Results 6Health News:US Oncology Reports First Quarter 2008 Results 7Health News:US Oncology Reports First Quarter 2008 Results 8Health News:US Oncology Reports First Quarter 2008 Results 9Health News:US Oncology Reports First Quarter 2008 Results 10Health News:US Oncology Reports First Quarter 2008 Results 11Health News:US Oncology Reports First Quarter 2008 Results 12Health News:US Oncology Reports First Quarter 2008 Results 13Health News:US Oncology Reports First Quarter 2008 Results 14Health News:US Oncology Reports First Quarter 2008 Results 15Health News:US Oncology Reports First Quarter 2008 Results 16Health News:US Oncology Reports First Quarter 2008 Results 17Health News:CorVel Announces Appearance at Bank of America Health Care Conference 2Health News:Workers With No Healthcare Protecting Kaiser Facilities, Security Contractor May Be Misleading California's Largest Healthcare Provider 2Health News:Physical Therapist Stresses Funding for Falls Prevention at National Safety Council Briefing 2
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... Akers, our ultimate goal is to provide ... and immediate treatment. Each year millions of ... die from late detection or undetected disease ... cripple nations., ,By developing, manufacturing and marketing ...
... RPR (Rapid Plasma Reagin) 18-mm Circle ... nontreponemal testing procedures for the serological ... Manual of Tests for Syphilis.* The ... the most widely used in the ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Medicine Products: